Loading...
•
Dec 31, 2023
Apellis Q4 2023 Earnings Report
Apellis reported Q4 2023 financial results, marked by the successful launch of SYFOVRE and continued growth of EMPAVELI.
Key Takeaways
Apellis Pharmaceuticals reported a total revenue of $146.4 million for Q4 2023, driven by $114.3 million from SYFOVRE and $24.4 million from EMPAVELI. The company's net loss was $88.5 million for the quarter. The company had $351.2 million in cash and cash equivalents as of December 31, 2023.
SYFOVRE generated $114.3 million in U.S. net product revenue in Q4 2023.
EMPAVELI generated $24.4 million in U.S. net product revenue in Q4 2023.
Total revenue for Q4 2023 was $146.4 million.
Apellis had $351.2 million in cash and cash equivalents as of December 31, 2023.
Apellis
Apellis
Apellis Revenue by Segment
Revenue by Segment
SYFOVRE U.S. Net Product Revenue
CapyFin.comEMPAVELI U.S. Net Product Revenue
CapyFin.comLicensing and Other Revenue
CapyFin.com Forward Guidance
Apellis is focused on bringing SYFOVRE to more patients, maximizing EMPAVELI, and advancing their pipeline.
Positive Outlook
- Continue strong execution in 2024
- Bringing SYFOVRE to even more patients in the U.S. and globally
- Maximizing EMPAVELI in PNH and C3G/IC-MPGN
- Advancing our earlier-stage pipeline
- Delivering on our mission for patients now and in the future
Revenue & Expenses
Visualization of income flow from segment revenue to net income